The Cardiometabolic Health Congress has announced Stanley Hazen, MD, PhD, Head of the Section for Preventive Cardiology and Rehabilitation of the Cleveland Clinic as its Keynote speaker for the 12th Annual CMHC, taking place October 4-7, 2017, at the Sheraton in Boston, MA. Specializing in preventive cardiovascular care, including the treatment of hyperlipidemia, diabetes, hypertension, and obesity, Dr. Hazen will discuss his groundbreaking work concerning gut microbes as a factor and therapeutic target in cardiometabolic diseases. Dr. Hazen has received numerous awards including election to membership in honorary societies in science and clinical arenas alike and also serves as reviewer and/or is on the editorial board for many scientific journals, including Circulation and the Journal of Lipid Research.
Dr. Braunwald, Professor at Harvard Medical School, is a world-renowned expert in the field of cardiovascular medicine and is believed to be the most frequently cited author in the field of cardiology, with more than 1000 publications in peer-reviewed journals. His landmark research includes the identification of hypertrophic cardiomyopathy as a clinical entity. As Founder and Chairman of the TIMI Study Group, one of their many achievements was the PROVE-IT TIMI 22 Trial, which demonstrated the benefit of intensive reduction of LDL cholesterol by statin therapy. Dr. Braunwald will be joining a panel at the 12th Annual CMHC that includes Drs. Christie Ballantyne, Paul Ridker, and Marc Sabatine to discuss the clinical trials FOURIER, REVEAL, and CANTOS.